GSK chops 650 jobs, vow­ing to shift more mon­ey to a weak R&D ef­fort

Glax­o­SmithK­line $GSK has once again brought out the axe, chop­ping 650 jobs as the phar­ma gi­ant slow­ly looks to fun­nel more mon­ey to the R&D side of the busi­ness.

The jobs are com­ing out of the US sales and back of­fice groups at GSK, which has re­peat­ed­ly looked to cut costs over the years with ma­jor re­or­ga­ni­za­tions like this. There are 100 “sup­port” jobs be­ing cut in each of their Philadel­phia and Re­search Tri­an­gle Park groups, with 450 sales reps in the field get­ting pink slips.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER